Tenaya Therapeutics, Inc. (TNYA)

4.6800 +0.0600 (+1.30%) At close: 04:00PM EDT

Tenaya Therapeutics, Inc.

171 Oyster Point Boulevard
Suite 500
South San Francisco, CA 94080
United States
650 825 6990
https://www.tenayatherapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 140

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Faraz Ali M.B.A.	CEO & Director	890.06k	N/A	1973
Dr. Deepak Srivastava M.D.	Scientific Founder, Chairman of Scientific Advisory Board & Director	120.5k	N/A	1967
Ms. Leone D. Patterson M.B.A.	Chief Financial & Business Officer	619.38k	N/A	1962
Dr. Whittemore G. Tingley M.D., PH.D.	Chief Medical Officer	645.79k	N/A	1968
Dr. Eric N. Olson Ph.D.	Scientific Founder & Member of Scientific Advisory Board	N/A	N/A	N/A
Dr. Bruce R. Conklin	Scientific Founder	N/A	N/A	N/A
Dr. Saptarsi Haldar M.D.	Scientific Founder	N/A	N/A	N/A
Dr. Sheng Ding Ph.D.	Scientific Founder	N/A	N/A	N/A
Dr. Benoit G. Bruneau Ph.D.	Scientific Founder	N/A	N/A	N/A
Dr. Kee-Hong Kim Ph.D.	Chief Technology Officer	N/A	N/A	1966

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Corporate governance

Tenaya Therapeutics, Inc.’s ISS governance QualityScore as of 1 May 2024 is 7. The pillar scores are Audit: 6; Board: 7; Shareholder rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.